mexiletine has been researched along with Kidney Failure, Chronic in 11 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We monitored the plasma levels of mexiletine in 20 dialysis patients with severe cardiac arrhythmias after repeated oral administration and the elimination by various dialysis procedures." | 3.67 | [Mexiletine in terminal renal failure and various dialysis procedures]. ( Aboudan, F; Evers, J; Finke, K; Messer, W, 1989) |
| "Mexiletine is a type 1B antiarrhythmic drug similar to lidocaine." | 1.28 | Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity. ( Chandrasekaran, K; Hammill, SC; Nora, MO; Reeder, GS, 1989) |
| "Mexiletine is an investigational antiarrhythmic drug eliminated primarily by hepatic metabolism." | 1.27 | Pharmacokinetics and nondialyzability of mexiletine in renal failure. ( Stone, WJ; Wang, T; Woosley, RL; Wuellner, D, 1985) |
| "Mexiletine (Mexitil) is an effective antiarrhythmic drug for the treatment of ventricular dysrhythmias." | 1.26 | Pharmacokinetics of mexiletine in renal insufficiency. ( Baudinet, G; Carlier, J; de Landsheere, C; Dresse, A; El Allaf, D; Henrard, L; Quinaux, N, 1980) |
| "Although pharmacodynamic factors are very important in regard to the need for dose adaptation of mexiletine, pharmacokinetic factors also play a role." | 1.26 | Adaptation of the dose of mexiletine according to pharmacokinetic data. ( Bogaert, M, 1980) |
| "2 Mexiletine was administered orally three times daily for 10 days to 15 patients with chronic renal failure (creatinine clearance lower than 30 ml/min) and to 9 subjects with normal renal function." | 1.26 | Pharmacokinetics of mexiletine in renal insufficiency. ( Carlier, J; Crochelet, L; Delapierre, D; Dresse, A; El Allaf, D; Henrard, L, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, Y | 1 |
| Wei, J | 1 |
| Farid, NA | 1 |
| White, SM | 1 |
| Jones, TE | 1 |
| Reece, PA | 1 |
| Fisher, GC | 1 |
| Baudinet, G | 1 |
| Henrard, L | 2 |
| Quinaux, N | 1 |
| El Allaf, D | 2 |
| de Landsheere, C | 1 |
| Carlier, J | 2 |
| Dresse, A | 2 |
| Bogaert, M | 1 |
| Nitsch, J | 1 |
| Steinbeck, G | 1 |
| Lüderitz, B | 1 |
| Crochelet, L | 1 |
| Delapierre, D | 1 |
| Evers, J | 1 |
| Messer, W | 1 |
| Aboudan, F | 1 |
| Finke, K | 1 |
| Nora, MO | 1 |
| Chandrasekaran, K | 1 |
| Hammill, SC | 1 |
| Reeder, GS | 1 |
| Kuno, T | 1 |
| Takahashi, S | 1 |
| Hibiya, K | 1 |
| Shimada, A | 1 |
| Nagura, Y | 1 |
| Takeuchi, M | 1 |
| Hatano, M | 1 |
| Wang, T | 1 |
| Wuellner, D | 1 |
| Woosley, RL | 1 |
| Stone, WJ | 1 |
1 trial available for mexiletine and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Effect of kidney, liver or heart insufficiency on blood mexiletine levels].
Topics: Arrhythmias, Cardiac; Biological Availability; Chromatography, Gas; Chronic Disease; Heart Failure; | 1982 |
10 other studies available for mexiletine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Mexiletine Suppressed Recurrent Ventricular Tachycardia Triggered by Hemodialysis in an Old Patient with LQT2.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Humans; Kidney Failure, Chro | 2019 |
Determination of mexiletine and its metabolites in serum by liquid chromatography with fluorescence detection.
Topics: Chemical Phenomena; Chemistry; Chromatography, Liquid; Fluorescence; Humans; Kidney Failure, Chronic | 1983 |
Mexiletine removal by peritoneal dialysis.
Topics: Humans; Kidney Failure, Chronic; Male; Mexiletine; Middle Aged; Peritoneal Dialysis; Peritoneal Dial | 1983 |
Pharmacokinetics of mexiletine in renal insufficiency.
Topics: Administration, Oral; Half-Life; Humans; Injections, Intravenous; Intestinal Absorption; Kidney Fail | 1980 |
Adaptation of the dose of mexiletine according to pharmacokinetic data.
Topics: Administration, Oral; Humans; Injections, Intravenous; Kidney Failure, Chronic; Kinetics; Mexiletine | 1980 |
Pharmacokinetics of mexiletine in renal insufficiency.
Topics: Aged; Female; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Mexiletine; Middle Aged; P | 1982 |
[Mexiletine in terminal renal failure and various dialysis procedures].
Topics: Adult; Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Heart Ventricles; Hemof | 1989 |
Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity.
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Conduction System; Humans; Kidney Fai | 1989 |
[The effects and pharmacokinetics of mexiletine in ventricular arrhythmia in maintenance hemodialysis patients].
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kidney Failure, Chronic; Male; Mexiletine; Middle Aged; | 1987 |
Pharmacokinetics and nondialyzability of mexiletine in renal failure.
Topics: Administration, Oral; Adult; Creatinine; Humans; Hydrogen-Ion Concentration; Kidney Failure, Chronic | 1985 |